Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of Berlim 25/20 association in the treatment of type 2 diabetes mellitus and dyslipidemia.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04602754
Study type Interventional
Source EMS
Contact Cassiano O Berto, BD
Phone +551938877724
Email pesquisa.clinica@ncfarma.com.br
Status Recruiting
Phase Phase 3
Start date December 1, 2023
Completion date August 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05563090 - Investigating the Syndrome Differentiation of Diabetic and Pre-diabetic Using Digitalized TCM Diagnostic Tools
Completed NCT05072990 - Type 2 Diabetes Mellitus With Obesity and Dyslipidemia Treated by Chinese Herbal Medicine
Completed NCT03932721 - EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial Phase 4
Terminated NCT03258281 - Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus Phase 4
Not yet recruiting NCT05128747 - Effectiveness of Nutritional Program Among Diabetic Patients N/A
Completed NCT05806723 - Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic Men Phase 4
Recruiting NCT04943926 - Dietary Strategies for Remission of Type 2 Diabetes N/A
Completed NCT05107063 - An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes
Completed NCT03784703 - Type 2 Diabetic Patients Maintained on Statin Therapy Phase 4
Recruiting NCT04882293 - Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP. Phase 3